Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $24.5 million.

  • Apellis Pharmaceuticals' Other Operating Expenses fell 2689.75% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.4 million, marking a year-over-year increase of 1714.75%. This contributed to the annual value of $117.7 million for FY2024, which is 10120.15% up from last year.
  • Apellis Pharmaceuticals' Other Operating Expenses amounted to $24.5 million in Q3 2025, which was down 2689.75% from $13.6 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Other Operating Expenses' 5-year high stood at $50.0 million during Q2 2021, with a 5-year trough of $82000.0 in Q2 2022.
  • In the last 5 years, Apellis Pharmaceuticals' Other Operating Expenses had a median value of $20.1 million in 2023 and averaged $18.6 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Other Operating Expenses plummeted by 9983.6% in 2022, and later skyrocketed by 1011829.27% in 2023.
  • Apellis Pharmaceuticals' Other Operating Expenses (Quarter) stood at $30.1 million in 2021, then crashed by 90.27% to $2.9 million in 2022, then surged by 580.75% to $19.9 million in 2023, then surged by 105.18% to $40.9 million in 2024, then tumbled by 39.96% to $24.5 million in 2025.
  • Its Other Operating Expenses was $24.5 million in Q3 2025, compared to $13.6 million in Q2 2025 and $34.4 million in Q1 2025.